Different predictive values of electrophysiological testing and autonomic assessment in patients surviving a sustained arrhythmic episode

Circ J. 2004 Jul;68(7):634-8. doi: 10.1253/circj.68.634.

Abstract

Background: Recent data suggest that the electrophysiological study (EPS) has limited value in the identification of high risk patients, so the aim of the present study was to evaluate if non-invasive measurement of baroreflex sensitivity (BRS), a marker of autonomic balance, provides additional prognostic information in patients surviving a sustained arrhythmic episode.

Methods and results: The study group comprised 112 post myocardial infarction patients consecutively referred for EPS following documented ventricular fibrillation (VF) (20), sustained ventricular tachycardia (VT) (74) or a syncopal episode with subsequently documented non-sustained VT at Holter monitoring (18). BRS was assessed according to the transfer function method. A cardioverter - defibrillator (ICD) was implanted in 97 patients. During follow-up (median 315 days), appropriate ICD discharge occurred in 53 patients, and 3 more patients died suddenly. Sustained VT was induced in 84% and 77% of patients who did or did not develop arrhythmia at follow-up (p=0.34). No differences were found in age, sex, infarct site, drug therapy, resting RR interval or cycle of induced VT. Left ventricular ejection fraction (LVEF) < or =35%, New York Heart Association (NYHA) class >2 and BRS < or =3.3 ms/mmHg were found to be univariate predictors of arrhythmia recurrence. Multivariate models were obtained after grouping patients according to a moderately or severely depressed LVEF. Among the patients with LVEF < or =35%, BRS < or =3.3 ms/mmHg emerged as the only significant risk predictor of arrhythmia occurrence (sensitivity, specificity, positive and negative predictive value = 79%, 74%, 83% and 68%, respectively), whereas NYHA class >2 was a significant predictor among patients with LVEF >35%.

Conclusions: Noninvasive BRS, but not EPS, is of value in predicting VT/VF episode recurrence in patients surviving a major arrhythmic event.

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Amiodarone / therapeutic use
  • Anti-Arrhythmia Agents / therapeutic use
  • Arrhythmias, Cardiac / diagnosis*
  • Arrhythmias, Cardiac / mortality
  • Arrhythmias, Cardiac / physiopathology*
  • Baroreflex / physiology
  • Death, Sudden, Cardiac
  • Electrophysiology / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Survival Analysis

Substances

  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Amiodarone